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An extract of the filamentous fungus Bionectria sp. (MSX 47401) showed both promising 
cytotoxic activity (>90% inhibition of H460 cell growth at 20 μg/mL) and antibacterial activity 
against methicillin-resistant Staphylococcus aureus (MRSA). A bioactivity-directed fractionation 
study yielded one new peptaibol (1) and one new tetramic acid derivative (2), and the fungus 
biosynthesized diverse secondary metabolites with mannose-derived units. Five known 
compounds were also isolated: clonostachin (3), virgineone (4), virgineone aglycone (5), AGI-7 
(6), and 5,6-dihydroxybisabolol (7). Compounds 5 and 7 have not been described previously 
from natural sources. Compound 1 represents the second member of the peptaibol structural class 
that contains an ester-linked sugar alcohol (mannitol) instead of an amide-linked amino alcohol, 
and peptaibols and tetramic acid derivatives have not been isolated previously from the same 
fungus. The structures of the new compounds were elucidated primarily by high-field NMR (950 
and 700 MHz), HRESIMS/MS, and chemical degradations (Marfey’s analysis). All compounds 
(except 6) were examined for antibacterial and antifungal activities. Compounds 2, 4, 








Fungi are a rich source of biologically active secondary metabolites that often possess unique 
structures. Estimates on the number of fungal species range between 1.5 M(1) and 5 M,(2) but 
fewer than 100 000 have been described taxonomically, and an even smaller number have been 
studied for pharmaceutical leads. The Dictionary of Natural Products(3) contains over 246 000 
compounds, of which approximately 14 260 (or 5.7%) have been isolated from fungi.(3, 
4)Despite these and other statistics that demonstrate that fungi are prolific at the production of 
bioactive secondary metabolites,(5-7) many pharmaceutical companies have minimized or 
eliminated natural products research programs.(8) In this context we have established a 
collaborative program between university researchers and biotechnology entrepreneurs to probe 
a library of over 55 000 filamentous fungi for new anticancer and antimicrobial leads.(9) 
 
An extract of the filamentous fungus Bionectria sp. (MSX 47401) showed both cytotoxic activity 
(>90% inhibition of H460 cell growth at 20 μg/mL) and antibacterial activity against methicillin-
resistant Staphylococcus aureus (MRSA). While this fungus was first isolated from twigs 
collected in 1990, to date neither cytotoxic nor antibacterial compounds had been isolated, even 
though it has been part of several different screening campaigns.(10) In this study, a suite of 
structurally diverse compounds were isolated, including peptaibols containing an ester-linked 
sugar alcohol (mannitol) instead of an amide-linked amino alcohol [a new peptaibol (1) and 
clonostachin (3)], a series of tetramic acid derivatives with mannosyl moieties [a new tetramic 
acid derivative (2) and virgineone (4)], the aglycone of 4 [virgineone aglycone (5)], one 
isocoumarin [AGI-7 (6)], and the bisabolane sesquiterpene 5,6-dihydroxybisabolol (7). Of the 
latter, compounds 5 and 7 have not been described previously from natural sources. The 
structures of the new compounds were elucidated primarily by high-field NMR (950 MHz), 
HRESIMS/MS, and chemical degradations (Marfey’s analysis). Finally, while potent 
cytotoxicity was not observed, compounds 2, 4, and 5 were antimicrobial, even showing activity 




Results and Discussion 
 
As part of ongoing studies to discover new anticancer and antimicrobial leads from filamentous 
fungi,(9, 11) an extract of the solid-phase culture of Bionectria sp. (MSX 47401) was examined 
for cytotoxic and antimicrobial properties. The 1:1 CHCl3–MeOH extract of the scaled-up 
fermentation of MSX 47401 was subjected to bioactivity-directed fractionation as monitored by 
inhibition of NCI-H460 (large cell lung carcinoma), MCF-7 (breast carcinoma), and SF-268 
(astrocytoma) cells lines.(12, 13) Interestingly, most of the fractions were inactive against the 
three cell lines, with the exception of F-4, which had a precipitate that concentrated the activity 
(>75% inhibition of the three cell lines at 20 μg/mL). The UV, 1H and 13C NMR, and HRESIMS 
data of the white precipitate matched favorably with those of the isocoumarin AGI-7 (6), 
reported by Lee et al.(14) from an unidentified fungus. Natural (cytogenin, sescandelin, and 
compound 6) and synthetic (NM-3 and other derivatives) isocoumarins have been studied 
extensively for their antitumor activity and cytotoxicity, possibly due to antiangiogenic 
properties.(14-16) In our assays, 6 was inactive, with an IC50 value of >10 μM. 
 
Fraction F-6 accounted for most of the mass (450 mg) after fractionation of the extract, and it 
was subjected to further purification using preparative RP-HPLC. This resulted in the isolation 
and characterization of a new peptaibol (1) and a new tetramic acid derivative (2) along with four 
known compounds, specifically clonostachin (3), virgineone (4), virgineone aglycone (5), and 
5,6-dihydroxybisabolol (7). 
 
Peptaibols 1 and 3 were isolated as white powders, and the molecular formulas were established 
as C79H136N14O25 and C78H134N14O25, respectively, on the basis of the HRESIMS (m/z1, 
1681.9863 [M + H]+; 3, 1667.9700 [M + H]+) and NMR data (Table 1), indicating 19 degrees of 
unsaturation for both compounds. The 1H NMR spectra in methanol-d3 of both 1 and3 each 
displayed 10 resonances between δH 7.30 and 8.70, which were assigned to the NH protons of 
the amide linkages. Similarly, 15 carbonyl signals were observed in the 13C NMR data between 
δC 170.0 and 176.0, confirming 1 and 3 to be peptides. Signals indicating a sugar alcohol were 
observed in the 1H (δH 3.40–5.30) and 13C (δC 60.0–73.0) NMR spectra for each compound. By 
analogy with compound 3,(17) the sugar moiety in 1 was linked to the peptide core via an ester 
bond to the carboxy terminus (CO, δC 172.0). Finally, the presence of a sharp singlet at δH 2.04 
in the 1H NMR spectrum of each compound suggested an acetylated N-terminal residue. 
Coupling these data with searches of the literature based on molecular formula, exact mass, and 
UV maxima in the Dictionary of Natural Products and SciFinder databases suggested that 
compound 3 was the known peptaibol clonostachin,(17) isolated fromClonostachys sp., which is 
an anamorph of Bionectria, while 1, a larger analogue, showed no match. From the 317 peptaibol 
sequences reported in the Peptaibol Database (http://peptaibol.cryst.bbk.ac.uk),(18, 
19) clonostachin (3) is the only peptaibol containing an ester-linked sugar alcohol (mannitol) 
instead of an amide-linked amino alcohol. The structure elucidation of 3 was based on Edman 
and chemical degradation and FABMS, EIMS, and NMR analysis; however, a complete NMR 
characterization was not performed.(17) 
 
TABLE 1 IS OMITTED FROM THIS FORMATTED DOCUMENT 
 
The amino acid sequences of compound 3 and related analogue 1 were examined by positive 
HRESIMS and HRESIMS/MS using higher-energy collisional dissociation (HCD).(20, 21) The 
full-scan HRESIMS spectra of 3 and 1 (Figure 1) exhibited several common in-source ions; in 
particular, b-type ions(22, 23) at m/z 1160.6924 and 1174.7075 suggested the presence of Aib-
Hyp and Iva/Val-Hyp labile bonds, corresponding to the formation of the undecapeptides Ac-
Aib1-Hyp2-Leu3-Iva4-Hyp5-Leu6-Iva7-Hyp8-Aib9-Iva10-Aib11 and Ac-Aib1-Hyp2-Leu3-
Iva4-Hyp5-Leu6-Iva7-Hyp8-Aib9-Iva10-Iva/Val11 for 3 and 1, respectively. From 
HRESIMS/MS spectra using HCD, a series of fragments (Figure 2) was observed via sodium ion 
adducts [M + Na]+ at m/z 1689.9517 and 1703.9677 of 3 and 1, respectively, confirming the 
sequence of each peptaibol. On the basis of the exact mass of the ion fragments a11*, the 
presence of Iva/Val11 in1, instead of Aib11 as seen in 3, was established. The replacement of 
Aib by Iva or Val has been reported, and some examples include chrysospermins B and 
D,(24) trichorzianines,(25) and asperelines,(26) among others. 
 
 
Figure 1. Full-scan HRESIMS spectra of peptaibols 3 and 1 (source voltage: 4.5 kV; tube lens 
voltage: 115 V; capillary voltage: 46 V). 
 
 
Figure 2. Positive HRESIMS/MS mass fragmentation patterns (HCD) of peptaibols 3 and 1, 
exhibiting bn or an* [an + Na] ions. 
 
The composition and absolute configuration of the residues were derived from the total acid 
hydrolysis of 3 and 1 followed by examination using a 10 min Marfey’s-UPLC method (Figure 
S15).(21, 27, 28) Thus, the residues in 3 were confirmed to be Aib (3), L-Hyp (4), l-Leu (2), d-
Iva (2), l-Iva (2), and l-Ile (1), as reported previously.(17) As expected, compound 1 showed an 
additional d-Iva11 (3) and one less Aib11 residue. Finally, the complete amino acid sequence of 
peptaibols 1 and 3 was established by reference to those confirmed for 3 by Edman 
degradation,(17) along with interpretation of a suite of high-field (950 MHz) NMR experiments. 
For peptaibol 1, the assignments of the 1H and 13C chemical shifts of the amino acid residues 
(Table 1) were complemented by 2D NOESY, TOCSY, and HMBC experiments (Figure 3). For 
instance, the complete spin systems of Leu3, Leu6, and Ile14 (NH and α-, β-, γ-, and δ-H 
resonances of the side chains) were clearly observed in the TOCSY spectrum (Figure 3). Ten NH 
singlets were attributed to the Aib, Leu, Iva, and Ile residues, which were confirmed by the 
HMBC correlations through 2JCH and 3JCH couplings between NH resonances and the carbonyl 
and α-C quaternary carbons around δC 172–174 and 51–59, respectively (Figure 3). Thus, 
HMBC correlations of the acetyl methyl carbon at δC 22.0 and the NH at δH 8.69 to the carbonyl 
carbon at δC 175.1 indicated the acetylated N-terminus of the Aib1 residue. In addition, the 
interactions of NH (δH 8.24, Leu3) with δC 172.9 (C═O, Hyp2) and 173.0 (C═O, Leu3), NH 
(δH7.76, Iva4) with C═O (Leu3) and δC 174.4 (C═O, Iva4), NH (δH 8.14, Leu6) with δC 173.2 
(C═O, Hyp5) and 173.3 (C═O, Leu6), NH (δH 7.75, Iva7) with C═O (Leu6) and δC 174.3 (C═O, 
Iva7), NH (δH 7.95, Aib9) with δC 170.1 (C═O, Hyp8) and 173.2 (C═O, Aib9), NH (δH 7.74, 
Iva10) with C═O (Aib9) and δC 174.3 (C═O, Iva10), NH (δH 7.73, Iva11) with C═O (Iva10) and 
δC 174.4 (C═O, Iva11), NH (δH 7.37, Iva13) with δC 171.9 (C═O, Hyp12) and 175.1 (C═O, 
Iva13), and NH (δH 7.74, Ile14) with C═O (Iva13) and δC 172.0 (C═O, Ile14) established the 
sequence of Ac-Aib1-Hyp2-Leu3-Iva4-Hyp5-Leu6-Iva7-Hyp8-Aib9-Iva10-Iva11-Hyp12-Iva13-
Ile14. Finally, the mannitol residue was shown to form an ester bond at the carboxy terminus 
(C═O, Ile14) with the methine proton at δH 5.24 on the basis of HMBC correlations. In 
summary, the structure of 3was verified, while the structure of the related analogue 1 was 
elucidated. So as to be consistent with the literature, the trivial name clonostachin B was ascribed 
to the latter. 
 
 
Figure 3. (a) Expansion of the TOCSY spectrum (in methanol-d3: ω2 = 7.7–8.3 ppm, ω1 = 0.8–
4.4 ppm) and (b) key NOESY and HMBC correlations observed in 1. 
 
Compounds 2, 4, and 5 were isolated as colorless powders. The main metabolite 4 was identified 
as the unusual tetramic acid glycoside named virgineone, recently isolated by Ondeyka and co-
workers from the saprotrophic fungus Lachnum virgineum using the Candida albicans fitness 
test.(29) Compound 5, the aglycone of 4, was also reported by the same research group, but as a 
hydrolysis product of 4. In this project 5 was isolated as a natural product or perhaps by 
hydrolysis during isolation, and the NMR and HRMS data were in agreement with those reported 
previously.(29) The configuration at positions C-2 and C-26 for compounds 4 and 5 was 
established as 2S and 26S by comparison of the NMR spectra and specific rotation values 
(see Supporting Information) with those reported for the synthetic isomers.(30) 
 
Compound 2 was assigned the molecular formula C40H61NO12 by HRESIMS, revealing an index 
of hydrogen deficiency of 11, which was one more than that of compound 4. The NMR spectra 
of 2 (Table 2) revealed nearly identical structural features to those found in virgineone (4), 
except for the methine signal for C-2 (δC 61.8) in 4, which was replaced with a quaternary carbon 
at δC 169.4 in 2. The side chain linked at C-4 was identical to that of 4, including the presence of 
a β-mannose moiety (elucidated by means of analyses of proton and COSY spectra and coupling 
constants as reported by Wangun et al.(31)) at the end of the aliphatic chain, one methyl carbon 
(δC 14.9), one aliphatic ketone (δC 213.1), and 17 methylene carbons in the aliphatic region 
(attributable to C-8–C-15 and C-17–C-25 through the analyses of the 2D NMR spectroscopic 
data), an anomeric methine (δH 4.51, δC 100.7), five oxymethines, and two oxymethylenes. The 
HMBC correlation data for the anomeric proton H-1″ and the methyl group H3-28 of 2 were 
essentially identical to those observed in 4, confirming the glycosidation at C-27 and the 
connectivity of the pyrrolone system with the aliphatic chain. The 1H NMR spectrum 
of 2(Table 2) also showed a typical AA′BB′ spin system attributable to a para-hydroxybenzene 
moiety at δH 6.71 (H-4′/H-6′) and 7.05 (H-3′/H-7′), which was further supported by COSY and 
HMBC experiments. The phenolic carbon C-5′ exhibited HMBC correlations to H-3′/7′ and H-
4′/6′, and the correlations from H-3′/7′ to C-1′ (δC 42.2) confirmed the position of the para-
hydroxybenzene residue at C-2. Finally, the HRESIMS analysis of 2 showed a major fragment 
ion at m/z 586.3724, ascribed to loss of the mannose moiety, and key fragment ions 
at m/z370.2176 and 398.1975 due to cleavage of the carbon bonds before (C-15/C-16) and after 
(C-16/C-17) the C-16 keto group, respectively, as observed for 4.(29) Compound 2, therefore, 




Compound 7 was isolated as a colorless oil, and its molecular formula C15H28O3 was assigned by 
HRESIMS (m/z 257.2110 [M + H]+). The NMR spectra and [α]D −48.7 value of 7 were 
consistent with those observed for the bisabolane sesquiterpene 5,6-dihydroxybisabolol.(32) This 
compound was isolated as one of the major products of the bioconversion of (−)-α-bisabolol 
byAspergillus niger by Miyazawa and co-workers.(32) However, this represents the first report 
of compound 7 as a natural product. 
The antibacterial (including several MRSA isolates) and antifungal properties of all compounds 
but 6 were examined as described previously.(21, 33, 34) The tetramic acid derivatives, 1,2-
dehydrovirgineone (2), virgineone (4), and virgineone aglycone (5), showed promising 
antimicrobial activity against S. aureus and several MRSA isolates, and compound 4 displayed 
moderate antifungal activity against Candida albicans, Cryptococcus neoformans, and A. 
niger(Table 3); these results were in agreement with those reported previously.(29) None of the 





In summary, a series of biogenetically diverse and bioactive compounds were isolated from 
aBionectria sp. (MSX 47401). The structures of the new peptaibol clonostachin B (1) and the 
known clonostachin (3) were fully elucidated by HRESIMS/MS using HCD, Marfey’s analysis, 
and high-resolution NMR (950 and 700 MHz) studies. Compound 1 represents the second 
peptaibol containing an ester-linked sugar alcohol (mannitol) instead of an amide-linked amino 
alcohol. Additionally, a new tetramic acid, 1,2-dehydrovirgineone (2), was identified along with 
the new natural product virgineone aglycone (5) and the known virgineone (4), isocoumarin 
AGI-7 (6), and sesquiterpene 5,6-dihydroxybisabolol (7). This represents the first report of 
compounds 5 and 7as natural products. All compounds but 6 were tested for antibacterial 
(including several MRSA isolates) and antifungal activities. Compounds 2, 4, and 5 showed 
promising antimicrobial activity against S. aureus and several MRSA isolates, whereas 1, 3, 
and 7 were inactive (MIC >118 μg/mL). Interestingly, both peptaibols 1 and 3, as well as the 





General Experimental Procedures 
Optical rotations and UV and CD spectra were recorded on a Rudolph Research Autopol III 
polarimeter (Rudolph Research), a Varian Cary 100 Bio UV–vis spectrophotometer (Varian 
Inc.), and an Olis DSM 17 CD spectrophotometer (Olis), respectively. NMR experiments were 
conducted in CDCl3, methanol-d4, or methanol-d3 with presaturation of the OH peak at δH 4.9 
ppm, using a JEOL ECA-500 (operating at 500 MHz for 1H, 125 MHz for 13C; JEOL Ltd.), a 
Bruker Ultrashield Plus 950 MHz with Avance III console and equipped with a QNP style 
cryoprobe (operating at 950.3 MHz for 1H; Bruker BioSpin Corp.), a Bruker Ultrashield Plus 600 
MHz with Avance III and equipped with a QNP style cryoprobe (operating at 600 MHz for 1H 
and 150 MHz for 13C; Bruker BioSpin Corp.), or an Agilent 700 MHz DD2 NMR system 
equipped with a 5 mm enhanced cold probe (operating at 700 MHz for 1H and 175 MHz for 13C; 
Agilent, Inc.). HRESIMS data were measured using an electrospray ionization source coupled to 
an LTQ Orbitrap XL system (Thermo Fisher Scientific) and equipped with an HCD cell. Data 
were collected in both positive and negative ionization modes via a liquid 
chromatographic/autosampler system that consisted of an Acquity UPLC system [Waters BEH 
C18 column (1.7 μm; 50 × 2.1 mm); Waters Corp.]. Flash chromatography was conducted with a 
CombiFlash Rf system using a RediSep Rf Si-gel Gold column (both from Teledyne-Isco). 
Analytical and preparative HPLC were carried out on a Varian Prostar HPLC system equipped 
with Prostar 210 pumps and a Prostar 335 photodiode array detector, with data collected and 
analyzed using Galaxie Chromatography Workstation software (version 1.9.3.2, Varian Inc.). For 
preparative (250 × 21 mm), semipreparative (250 × 10 mm), and analytical (250 × 4.6 mm) 
HPLC, Gemini-NX 5 μm or Synergi Max-RP 80 4 μm columns (all from Phenomenex) were 
utilized. For UPLC analysis, a BEH C18 (1.7 μm; 50 × 2.1 mm; Waters Corp.) column was used. 
Reference standards of amino acids and Marfey’s reagent were obtained from Sigma-Aldrich. 
All other reagents and solvents were obtained from Fisher Scientific and were used without 
further purification. 
 
Producing Organism and Fermentations 
Mycosynthetix fungal strain 47401 was isolated by Dr. Barry Katz in May 1990 from leaf litter 
and leaves collected in a humid mountain forest. The growth conditions for the solid-phase 
fermentations were as described previously(12, 35) and are outlined in the Supporting 
Information. For molecular identification of strain MSX 47401, the internal transcribed spacer 
(ITS) regions 1 and 2 and 5.8S nrDNA were sequenced.(36) Detailed methodology for DNA 
extraction, PCR amplification, and sequencing is described in the Supporting Information. The 
combined ITS and LSU sequence was deposited in GenBank (accession no. KC222025). The 
complete ITS sequence including both spacers and the 5.8S region of MSX 47401 (∼470 base 
pairs) was compared with GenBank’s database(37) using the BLAST search.(38) BLAST search 
and maximum likelihood (ML) analyses revealed phylogenetic affinities of MSX 47401 with 
members of the order Hypocreales. Further multiple sequence alignment and additional 
phylogenetic analysis indicated that MSX 47401 shared affinities with only two strains 
ofBionectria rossmaniae (AF358227 and AF210665) with significant bootstrap support values 
(Figure S1). 
 
Extraction and Isolation 
To the large-scale solid fermentation culture of MSX 47401 (2.8 L Fernbach flask containing 
150 g of rice and 300 mL of H2O, which was inoculated using seed cultures grown in the YESD 
media and incubated at 22 °C for 14 days; Supporting Information) was added 500 mL of 1:1 
MeOH–CHCl3, and the mixtures were shaken for 16 h on a reciprocating shaker. The solution 
was filtered, and equal volumes of H2O and CHCl3 were added to the filtrate to bring the total 
volume to 2 L; the mixture was stirred for 2 h and then transferred into a separatory funnel. The 
bottom layer was drawn off and evaporated to dryness. The extract was defatted by stirring 
vigorously for 30 min in a mixture of 100 mL of 1:1 MeOH–CH3CN and 100 mL of hexane and 
then partitioned in a separatory funnel. The bottom layer was collected and evaporated to 
dryness. The defatted large-scale extract (1.3 g) was adsorbed onto a minimal amount of Celite 
545 (Acros Organics) and dried with mixing via a mortar and pestle. This material was 
fractionated via flash chromatography on a 40 g RediSep Rf Gold Si-gel column, using a 
gradient solvent system of hexane–CHCl3–MeOH at a 40 mL/min flow rate and 53.3 column 
volumes over 63.9 min. Fractions were collected every 25 mL and pooled according to UV and 
ELSD profiles. From fractions 56–71 (F-4), which were combined and evaporated (96 mg), a 
precipitate (compound 6; 2.8 mg) was isolated (>75% inhibition of the three cell lines at 20 
μg/mL). Preparative HPLC purification (Synergi column) of fraction 6 (F-6, 450 mg) using a 
linear gradient (40 to 85% of CH3CN–0.1% aqueous formic acid over 30 min at a flow rate of 
21.2 mL/min) yielded eight subfractions. Purification of subfraction 2 (24 mg) by 
semipreparative HPLC (Gemini column, various ratios of CH3CN in 0.1% aqueous formic acid) 
afforded compounds 1 (1.5 mg) and 3 (2.1 mg). Preparative HPLC (Gemini column, various 
ratios of CH3CN in 0.1% aqueous formic acid) of subfraction 3 (99.0 mg) and further 
purification of the subsequent fractions by semipreparative HPLC (Gemini column, various 
ratios of CH3CN in 0.1% aqueous formic acid) afforded compounds 2 (0.8 mg) and 4 (62.1 mg). 
A second large-scale solid fermentation culture of MSX 47401 was extracted (515 mg) and 
fractionated in the same fashion as shown above. Preparative HPLC (Gemini column with a 
linear gradient of 20 to 100% of CH3CN–0.1% aqueous formic acid over 45 min at a flow rate of 
21.2 mL/min) of subfractions 3 (70 mg) and 4 (66 mg) yielded compound 4 (9.3 mg) from the 
former and compounds 5 (3.6) mg and 7 (3.1 mg) from the latter. 
 
Clonostachin B (1): 
white powder; [α]D26 +3.7 (c 0.1, MeOH); UV (MeOH) λmax (log ε) 279.0 (2.90), 221 (3.33) nm; 
CD (MeOH) λmax (Δε) 225 (+1.0), 237 (−2.2), and 292 (−0.9); 1H NMR (methanol-d3, 950.30 
MHz) and 13C NMR (methanol-d3, 238.95 MHz), see Table 1; HRESIMS m/z 1681.9863 [M + 
H]+(calcd for C79H137N14O25 1681.9874). 
 
1,2-Dehydrovirgineone (2): 
colorless powder; [α]D26 +3.6 (c 0.08, MeOH); UV (MeOH) λmax (log ε) 349 (3.03), 284 (3.23), 
226 (3.19) nm; CD (MeOH) λmax (Δε) 219 (+0.8), 251 (−0.4), and 306 (+0.2); 1H NMR 
(methanol-d4, 500 MHz) and 13C NMR (methanol-d4, 125 MHz), see Table 2; 
HRESIMS m/z 748.4246 [M + H]+ (calcd for C40H62NO12 748.4267). 
 
Marfey’s Analysis of 1 and 3 
The method was based on Ayers et al.(21) (see Supporting Information) with the following 
modifications. UPLC conditions were 15–80% CH3CN in H2O over 10 min using a BEH column 
with the eluent monitored at 340 nm. 
 
Cytotoxicity Assay 
The cytotoxicity measurements against the MCF-7(39) human breast carcinoma (Barbara A 
Karmanos Cancer Center), NCI-H460(40) human large cell lung carcinoma [HTB-177, 
American Type Culture Collection (ATCC)], and SF-268(41) human astrocytoma (NCI 




MIC measurements were performed as described,(21, 33, 34) with the single modification of 
dilution of cultures in growth medium (10- to 100 000-fold). Undiluted cultures and dilutions 
were used as inocula for MIC measurements. All measurements were made in duplicate. 
 
Supporting Information 
Information about the producing organism and its fermentation, the HRMS data and [α]D values 
for compounds 4–6, a phylogram of the most likely tree, NMR spectra for compounds 1–7, and 
Marfey’s analysis of 1 and 3. This material is available free of charge via the Internet at 
http://pubs.acs.org. 
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